We are live on ! Find out more
LJPC

La Jolla Pharmaceutical Company
LJPC

Delisted

LJPC was delisted on the 19th of August, 2022.

Back to rankings

41 hedge funds and large institutions have $53.9M invested in La Jolla Pharmaceutical Company in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 17 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

9% less funds holding

Funds holding: 45 → 41 (-4)

24% less capital invested

Capital invested by funds: $70.4M → $53.9M (-$16.6M)

53% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 17

67% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 6

Holders
41
Holders Change
-4
Holders Change %
-8.89%
% of All Funds
0.69%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
2
Increased
8
Reduced
17
Closed
6
Calls
$47K
Puts
–
Net Calls
+$47K
Net Calls Change
-$55K

Top Buyers

Rank Fund Capital Flow
1
HP
HealthInvest Partners
Sweden
+$2.17M
2
ONB
Old National Bancorp
Indiana
+$161K
3
Renaissance Technologies
Renaissance Technologies
New York
+$122K
4
OSAM
O'Shaughnessy Asset Management
Connecticut
+$67.7K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$41.5K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$217K
2
Two Sigma Advisers
Two Sigma Advisers
New York
-$149K
3
Millennium Management
Millennium Management
New York
-$141K
4
GC
Globeflex Capital
California
-$133K
5
Two Sigma Investments
Two Sigma Investments
New York
-$118K
Name Holding Trade Value Shares
Change 		Change in
Stake
PNC Financial Services Group
26
PNC Financial Services Group
Pennsylvania
$22K – – –
Bank of America
27
Bank of America
North Carolina
$17K -$4.62K -1,185 -18%
Barclays
28
Barclays
United Kingdom
$17K – – –
MAM
29
Meeder Asset Management
Ohio
$13K -$596 -153 -4%
Wells Fargo
30
Wells Fargo
California
$9K +$8 +2 +0.1%
EIP
31
Ellis Investment Partners
Pennsylvania
$8K – – –
TRCT
32
Tower Research Capital (TRC)
New York
$7K -$5.79K -1,486 -42%
Osaic Holdings
33
Osaic Holdings
Arizona
$4K +$5.45K +1,400 New
SWA
34
SOA Wealth Advisors
New York
$3K – – –
TSWM
35
Tyler-Stone Wealth Management
Ohio
$2K – – –
UBS Group
36
UBS Group
Switzerland
$1K -$7.28K -1,868 -84%
Group One Trading
37
Group One Trading
Illinois
$1K -$1.02K -261 -44%
Royal Bank of Canada
38
Royal Bank of Canada
Ontario, Canada
$1K – – –
BNP Paribas Financial Markets
39
BNP Paribas Financial Markets
France
$3 – – –
Citadel Advisors
40
Citadel Advisors
Florida
– -$217K -50,873 Closed
Two Sigma Advisers
41
Two Sigma Advisers
New York
– -$149K -34,900 Closed
Two Sigma Investments
42
Two Sigma Investments
New York
– -$118K -27,544 Closed
Goldman Sachs
43
Goldman Sachs
New York
– -$59K -13,718 Closed
OQS
44
Occudo Quantitative Strategies
Florida
– -$58K -13,541 Closed
APA
45
American Portfolios Advisors
New York
– -$4.27K -1,000 Closed
JP Morgan Chase
46
JP Morgan Chase
New York
– -$1.33K -341 -88%
Simplex Trading
47
Simplex Trading
Illinois
– -$1.04K -267 -81%
1
2

LJPC Hedge Fund Activity: Q2 2022 in Review

41 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q2 2022, worth a combined $53.9M — down 24% from $70.4M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of LJPC and 2 opened new positions — a net loss of 4 holders — while 17 trimmed existing stakes and 8 added.

The largest buyer was HealthInvest Partners, adding an estimated $2.17M. The largest seller was Citadel Advisors, exiting entirely with an estimated $217K sold.

  • 41 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q2 2022, down from 45 in Q1 2022.
  • Funds reported $53.9M of La Jolla Pharmaceutical Company stock for Q2 2022, down 24% quarter-over-quarter.
  • 2 funds opened new La Jolla Pharmaceutical Company positions in Q2 2022 and 6 closed out, a net change of -4 holders.
  • The largest La Jolla Pharmaceutical Company buyer in Q2 2022 was HealthInvest Partners, an estimated $2.17M added.
  • The largest La Jolla Pharmaceutical Company seller in Q2 2022 was Citadel Advisors, an estimated $217K sold.

Based on aggregated 13F filings for Q2 2022.